Table 1.
Baseline characteristics of patients with isolation of Aspergillus in respiratory samples.
| IPA (Proven, Probable, Possible) (n: 140) | No Aspergillosis (Colonization) | p | |
|---|---|---|---|
| (n: 100) | |||
| Age (years ± SD) | 66.4 (±12.6) | 66.6 (±16.4) | 0.89 |
| Gender (male) | 59.40% | 60.60% | 0.89 |
| Tracheobronquitis | 3.60% | 0 | 0.015 |
| Hemoptysis | 11.40% | 7.10% | 0.37 |
| Type of pulmonary infiltrate | |||
| -No infiltrate | 2.90% | 53% | <0.001 |
| -Bilateral, ground-glass opacities | 75.00% | 28.00% | <0.001 |
| -Nodular infiltrate | 9.30% | 3.00% | 0.067 |
| -Caveat | 3.60% | 0 | 0.077 |
| -Pulmonary embolism | 9.30% | 6.00% | 0.46 |
| -Pleural fluid | 31.40% | 32.50% | 0.73 |
| Diabetes | 26.80% | 21.20% | 0.36 |
| Diabetes (insulin required) | 2.20% | 1.00% | 0.64 |
| Renal insufficiency (chronic) | 10.90% | 7.10% | 0.37 |
| Renal insufficiency (acute or chronic) | 35.00% | 24.00% | 0.87 |
| Hepatic insufficiency (acute or chronic) | 10.90% | 9.10% | 0.82 |
| Active hematologic disorder | 8.00% | 0 | 0.003 |
| Progenitor hematologic transplant | 2.90% | 1.00% | 0.4 |
| Solid organ transplant | 1.40% | 1.00% | 1 |
| Active Solid tumor | 5.80% | 5.10% | 1 |
| Active chemotherapy | 3.60% | 3.00% | 0.84 |
| Corticoid therapy | 10.1 | 3 | 0.04 |
| Corticoid therapy (>15 mg prednisone/d) | 4.30% | 0 | 0.04 |
| Therapy including biologics | 2.90% | 1.00% | 0.4 |
| Neutrophils <100/µL (last 3 months) | 1.40% | 0 | 0.51 |
| Neutrophils count (±SD) | 8380 (±6100) | 8076 (±5400) | 0.7 |
| Lymphocytes count (±SD) | 1304 (±1472) | 1492 (±1347) | 0.33 |
| Platelets count (±SD) | 223.6 × 103 (±106.2 ×103) | 230.7 × 103 (±113.7 × 103) | 0.63 |
| D-Dimer count (±SD) | 6611 (±13,049) | 2540 (±2834) | 0.17 |
| IL-6 (±SD) | 227.5 (±706.5) | 826.5 (±1850.5) | <0.001 |
| CRP (±SD) | 85.9 (±88.0) | 119.6 (±119.0) | 0.03 |
| Previous aspergillosis | 1.40% | 3.00% | 0.65 |
| Oxygen any requirements | 88.60% | 62% | <0.001 |
| Oxygen high requirements | 68.60% | 45.00% | <0.001 |
| ICU admission | 63.60% | 42.00% | 0.001 |
| Mechanical ventilation | 58.60% | 39.00% | <0.001 |
| Inotropic therapy | 50.70% | 33.00% | 0.008 |
| Pronation required | 48.60% | 21.00% | <0.001 |
| ECMO | 2.10% | 1.00% | 0.17 |
| Corticoid therapy previous (any dose) | 83.60% | 41.40% | <0.001 |
| Corticoid therapy previous (>250 mg/d) | 3.60% | 1.00% | 0.4 |
| Bacterial infection | 87.10% | 65.00% | <0.001 |
| CMV infection | 43.50% | 40.00% | 1 |
| CMV disease | 12.90% | 25.00% | 0.28 |
| Hospitalization total days | 30.5 d (±25.4) | 22.5 d (±33.3) | 0.04 |
| ICU total days | 16.5 d (±19.7) | 10.8 d (±17.8) | 0.029 |
| Dead | 37.10% | 34.00% | 0.61 |
| SARS-CoV-2 infection | 77.10% | 24.00% | <0.001 |
| Autopsy available | 5.00% | 24% | <0.001 |
| Autopsy with IPA confirmation | 2.90% | - | - |
ECMO: extracorporeal membrane oxygenation. IL-6: Interleukin-6. CMV: Cytomegalovirus. CRP: C-reactive protein. ICU: Intensive care unit.